Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medical products maker Cardinal Health is combining its Outcomes business with pharmacy tech firm Transaction Data Systems. The deal will give Cardinal Health a minority stake in the combined entity, with Debbie Weitzman, CEO of Cardinal Health's pharmaceutical segment, joining the Transaction Data Systems (TDS) board of directors, according to a Monday (June 5) press release.

Cardinal Health's ‘Outcomes' Business Merges With Pharmacy Tech Firm TDS

Cardinal Health's Outcomes™ business will combine with Transaction Data Systems to offer improved patient engagement and clinical pharmacy solutions, expanding connections between payers and pharma to its nationwide pharmacy network DUBLIN, Ohio , June 5, 2023 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced it has signed a definitive agreement to contribute its Outcomes™ business to Transaction Data Systems (TDS), a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a minority stake in the combined entity. Under the terms of the agreement, Cardinal Health's pharmaceutical segment CEO, Debbie Weitzman, will be appointed to the TDS board of directors.

Cardinal Health announces the merger of its Outcomes™ business into Transaction Data Systems and related partnership

Block

Cardinal Health, a manufacturer and distributor of medical and laboratory products, has teamed up with Square to provide payment solutions for independent pharmacies. This collaboration aims to help independent pharmacies increase operational efficiency, stay current with customer payment preferences, and access integrated software tools for their business.

Cardinal Health Teams With Square on Pharmacy POS Payments

DUBLIN, Ohio and SAN FRANCISCO , May 31, 2023 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today launched modern payment solutions, powered by Square, to help independent pharmacies increase operational efficiency, stay current with customer payment preferences, and access integrated software tools for their business. The collaboration with Square allows Cardinal Health to offer its independent pharmacy customers access to innovative products that can seamlessly manage business operations, integrate flexible payment options for in-store, online and delivery purchases, and reduce payment processing costs.

Cardinal Health launches Modern Commerce Solutions for Retail Independent Pharmacies powered by Square

Anheuser-Busch InBev

Disney

Target

American Express

Campbell Soup

AT&T

When looking at a number of overvalued blue-chip stocks, “Sell in May and Go away” fits. Typically, blue-chip stocks are generally among the safest stocks to own.

7 Overvalued Blue-Chip Stocks to Sell Before June 2023

In the past year, Cardinal Health (CAH: +50.95%) has rallied significantly, with share price action superior to both the broad market (SPY: +5.51%) and the healthcare industry (IXHC: +12.81%). This reflects a 34.80% in free cash flow from 2021-22 to $2.73bn and revenue growth of 11.62% in the same period.

Cardinal Health: Focus On Core Strengths And Operational Efficiency Enabling Margin Expansion

Cardinal Health reported solid third quarter results and raised full-year guidance. In the last twelve months, Cardinal Health's stock outperformed as the stock price saw a reversion to the mean from previously extreme undervaluation.

Cardinal Health: Not A Long-Term Investment

W.W. Grainger

McDonald's

Banking on recent strengths, investors should place their bets on sound stocks like McDonald's (MCD), W.W. Grainger (GWW) & Cardinal Health (CAH) that are poised to scale upward along with the broader S&P 500 Index.

3 Top S&P 500 Stocks to Buy as Index Tastes 4200 Mark

Eli Lilly

Merck

Everyone seems to be talking about semiconductors, artificial intelligence (AI) and mega-cap tech. However, no one seems to be talking about healthcare stocks to buy.

Shhh! 3 Healthcare Stocks Quietly Hitting 52-Week Highs

Boyd Gaming

Ford Motor Company

NXP Semiconductors

Here are five stocks that meet our screening criteria - CAH, BYD, F, NXPI, AIG.

5 Attractive Value Picks Based on Discounted PEG

Apple

Arbor Realty Trust

Archer-Daniels-Midland Company

Aflac

Assured Guaranty

Apartment Income REIT Corp

Amgen

Ameriprise Financial

Artesian Resources

Ashland Global Hlds

Atmos Energy

Atlantic Union Bankshares Corp

Armstrong World Industries

American States Water

Black Hills

Brown & Brown

BWX Technologies

Caterpillar

Cabot

Cogent Communications Holdings

Cognex

Cummins

Costco

Carlisle Companies

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.

Dividend Champion, Contender, And Challenger Highlights: Week Of May 14

AbbVie

Chevron

Realty Income Corp

PepsiCo

Walgreens

It seems almost humorous that bullish Wall Street strategists and even more bullish financial media talking heads continue to tout that a Federal Reserve pause, and perhaps even a rate cut, may soon be in the cards.

Recession and Market Sell-Off Likely Coming Soon: 7 Safe Dividend Aristocrats to Buy Now

Cardinal Health CAH said Thursday its board has approved an increase in the company's quarterly dividend to 50.06 cents a share. The company paid out 49.57 cents a share in the last quarter.

Cardinal Health raises quarterly dividend to 50.06 cents a share

Chubb

Diageo

General Electric

GlaxoSmithKline

Illinois Tool Works

Johnson Controls

Kimberly-Clark

Coca-Cola

Leggett & Platt

Mondelez

Altria

Philip Morris

Markets continue to look shaky, real estate is starting to crack, precious metals doing pretty well but are still manipulated well below true value and the crypto world has started to thaw but nowhere near mania mode, yet. These lows and uncertain times are when the real profits and income is generated for the future.

Dividend Portfolio Update: April 2023

Cardinal Health's (CAH) fiscal third-quarter results benefit from the Pharmaceutical segment's solid performance.

Cardinal Health (CAH) Beats on Q3 Earnings, Ups '23 EPS View

Cardinal Health, Inc. (NYSE:CAH ) Q3 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Kevin Moran - Vice President, Investor Relations Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants Michael Cherny - Bank of America Lisa Gill - JPMorgan Kevin Caliendo - UBS Elizabeth Anderson - Evercore ISI Eric Percher - Nephron George Hill - Deutsche Bank Eric Coldwell - Baird Steven Valiquette - Barclays Daniel Grosslight - Citi Charles Rhyee - TD Cowen Jonathan Yong - Credit Suisse Kristen Shuman - Jefferies Operator Hello and welcome to the Third Quarter Fiscal Year 2023 Cardinal Health Incorporated Earnings Conference Call. My name is George.

Cardinal Health, Inc. (CAH) Q3 2023 Earnings Call Transcript

Cardinal Health (CAH) came out with quarterly earnings of $1.74 per share, beating the Zacks Consensus Estimate of $1.48 per share. This compares to earnings of $1.45 per share a year ago.

Cardinal Health (CAH) Tops Q3 Earnings and Revenue Estimates

Revenue increased 13% to $50.5 billion GAAP1 operating earnings were $572 million; GAAP diluted EPS was $1.34 Non-GAAP operating earnings increased 11% to $606 million; non-GAAP diluted EPS increased 20% to $1.74 Fiscal year 2023 non-GAAP EPS guidance raised and narrowed to $5.60 to $5.80, from $5.20 to $5.50 Fiscal year 2023 adjusted free cash flow guidance raised and narrowed to $2.0 to $2.3 billion, from $1.5 to $2.0 billion DUBLIN, Ohio , May 4, 2023 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2023 revenues of $50.5 billion, an increase of 13% from the third quarter of fiscal year 2022. Third quarter GAAP operating earnings were $572 million and GAAP diluted earnings per share (EPS) were $1.34.

Cardinal Health Reports Third Quarter Fiscal Year 2023 Results and Raises Fiscal Year 2023 Non-GAAP EPS Guidance

Ligand Pharmaceuticals

Cardinal Health (CAH) and Ligand Pharmaceuticals (LGND) are two healthcare companies that investors certainly want to watch going into their quarterly reports.

2 Medical Stocks to Buy Before Earnings

SAN DIEGO--(BUSINESS WIRE)--The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Cardinal Health Securities Litigation: UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF OHIO EASTERN DIVISION LOUISIANA SHERIFFS' PENSION & RELIEF FUND, Individually and on Behalf of All Others Similarly Situated,   Plaintiff,   vs.   CARDINAL HEALTH, INC., et al.,   Defendants.   ) ) ) ) ) ) ) ) ) ) ) ) No. 2:19-cv-03347   CLASS ACTION   District Judge Edmund A. Sargus.

Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Cardinal Health Securities Litigation

News for Cardinal Health Stock (CAH)